Organization | Almirall

Almirall Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Barcelona Spain (1943)

Organization Overview

First Clinical Trial

2008

NCT00987246

First Marketed Drug

1963

flurandrenolide (cordran)

First NDA Approval

1963

flurandrenolide (cordran)

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (13)

azelaic acid (azelex) (1995 NDA)

clindamycin (cleocin) (2010)

dapsone (aczone) (2016)

doxycycline (vibramycin) (1989)

fluorouracil (efudex) (1971)

flurandrenolide (cordran) (1963 NDA)

ketoconazole (nizoral) (2006)

mequinol (Solage) (1999)

prednisone (meticorten) (2006)

retapamulin (altabax) (2007)

sarecycline hydrochloride (seysara) (2018)

tirbanibulin (Klisyri) (2020)

tretinoin (Retin-A) (1999)

Drugs in Phase 4 Trials (7)

aclidinium (tudorza pressair) (1 trial)

diclofenac (voltaren) (1 trial)

dimethyl fumarate (tecfidera) (1 trial)

pidotimod (1 trial)

tildrakizumab (3 trials)

tiotropium (spiriva) (1 trial)

tirbanibulin (Klisyri) (2 trials)

Drugs in Phase 3 Trials (15)

Key: Almirall (10) Acquired (5)

calcipotriene (dovonex) (2 trials)

finasteride (Proscar) (2 trials)

fluorouracil (efudex) (1 trial)

lebrikizumab (1 trial)

loceryl (1 trial)

p-3058 (2 trials)

salicylic acid (1 trial)

sativex (1 trial)

terbinafine (lamisil) (1 trial)

Drugs in Phase 2 Trials (11)

betamethasone (celestone) (2 trials)

bexarotene (targretin) (2 trials)

danegaptide (1 trial)

estradiol (progynon depot) (3 trials)

las189961 (3 trials)

las189962 (3 trials)

las41004 (4 trials)

mometasone (elocon) (1 trial)

octenidine (3 trials)

prednicarbate (dermatop) (3 trials)

tazarotene (tazorac) (1 trial)

Drugs in Phase 1 Trials (3)

fluticasone (cutivate) (1 trial)

furamag (1 trial)

salmeterol (serevent) (1 trial)

Indications

Approved Indications

Pigmentation

Rosacea

Skin Diseases

Experimental Indications (Clinical Trials, Phases 1-4)

Candidiasis (Phase 2)

Chronic Disease (Phase 4)

Communicable Diseases (Phase 4)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Infections (Phase 4)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Lung Diseases (Phase 4)

Multiple Sclerosis (Phase 3)

Muscle Spasticity (Phase 3)

Onychomycosis (Phase 3)

Psoriasis (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Respiratory Tract Infections (Phase 4)

Sclerosis (Phase 3)

Skin Diseases (Phase 2)

Tinea (Phase 2)

Tinea Pedis (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 35
# of Trial APIs: 36